Form 4: AnaptysBio Chief Medical Officer Paul F. Lizzul Reports Stock Transactions

Chief Medical Officer of AnaptysBio, Paul F. Lizzul, reports acquisition and disposal of company stock, including shares acquired through the Employee Stock Purchase Plan (ESPP) and sales under a pre-arranged trading plan.

Summary

• Paul F. Lizzul, Chief Medical Officer of AnaptysBio, reported transactions involving the company's common stock on July 18, 2024.
• Lizzul acquired 1,500 shares of common stock through the company's ESPP at a price of $18.5 per share.
• Simultaneously, Lizzul sold 1,500 shares at $35 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on September 22, 2023.
• Following these transactions, Lizzul directly owns 11,618 shares of AnaptysBio common stock.
• Lizzul also holds options to purchase 88,500 shares that vest over time, and additional options to purchase 297,610 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock transactions by an officer. The ESPP purchase is mildly positive, while the sale is neutral given the pre-arranged trading plan.

Positives

• The acquisition of shares through the ESPP demonstrates the officer's investment in the company's future.
• The use of a 10b5-1 trading plan suggests a proactive approach to managing stock holdings while avoiding insider trading concerns.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may influence investor sentiment, although the use of a 10b5-1 plan mitigates concerns about opportunistic trading.

Key Dates